Skip to main content
. 2013 Oct 31;9(1):12–20. doi: 10.2215/CJN.02730313

Table 2.

Demographic and clinical characteristics according to the development of AKI by the KDIGO definition during hospitalization

Characteristic No AKI All AKI Stagesa Stage 1 Stage 2 Stage 3
Participants, n 26,122 5848 4148 1001 699
Demographic data
 Age, yr 50 (35–66) 64 (52–75) 64 (53–75) 62 (52–72) 64 (52–74)
 Men, % 31.9 50.4 50.3 46.0 57.1
 Race, %
 White 71.5 79.4 79.6 79.6 78.0
 Black 11.1 8.6 8.5 8.3 10.2
 Hispanic 7.8 5.2 5.5 4.5 4.7
 Other 9.7 6.8 6.5 7.6 7.2
Laboratory values on admissionb
 Serum creatinine, mg/dl 0.8 (0.7–1.0) 1.0 (0.8–1.5) 1.0 (0.7–1.3) 1.1 (0.8–1.5) 1.9 (1.0–3.6)
 Hemoglobin, g/dl 11.8 (10.4–13.0) 11.1 (9.7–12.7) 11.2 (9.9–12.7) 11.1 (9.7–12.8) 10.3 (8.9–11.8)
 White blood cell count, 1000/μl 8.7 (6.5–11.6) 8.9 (6.3–12.8) 8.7 (6.3–12.4) 9.6 (6.5–14.1) 9.3 (5.9–14.3)
 Platelet count, 1000/μl 245 (193–311) 234 (167–315) 236 (172–315) 233 (158–319) 220 (117–310)
 BUN, mg/dl 13 (10–18) 19 (13–31) 18 (12–27) 20 (14–33) 35 (19–63)
 Sodium, mmol/L 137 (135–139) 137 (134–139) 137 (134–139) 137 (133–139) 136 (133–139)
 CO2, mmol/L 25 (23–27) 24 (22–27) 25 (22–27) 24 (21–27) 22 (19–26)
 Albumin, g/dl 3.7 (3.3–4.0) 3.5 (3.0–3.9) 3.6 (3.1–4.0) 3.4 (2.9–3.9) 3.2 (2.8–3.7)
 Total bilirubin, mg/dl 0.4 (0.3–0.6) 0.5 (0.3–0.8) 0.5 (0.3–0.7) 0.5 (0.3–0.8) 0.5 (0.3–1.0)

Results are presented as medians with interquartile ranges or column percentages. KDIGO, Kidney Disease Improving Global Outcomes.

a

P<0.001 for all comparisons between patients with AKI and without AKI.

b

The following indicate the laboratory values that were missing in patients without AKI and with AKI, respectively: hemoglobin, 31.1% and 1.4%; white blood cell count, 31.1% and 1.4%; platelet count, 31.1% and 1.4%; BUN, 30.5% and 1.1%; sodium, 33.7% and 1.5%; CO2, 33.7% and 1.5%; albumin, 62.4% and 26.1%; total bilirubin, 62.8% and 26.9%; and serum creatinine, 28.5% and 0.0%.

HHS Vulnerability Disclosure